07 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Boehringer Ingelheim is closing down its generic sterile injectables manufacturing arm, Ben Venue Laboratories, by the end of 2013, giving away pink slips to over 1,100 employees.
The company has stated that although interim controls implemented to assure product quality have been effective to date, in the long term, they are not sustainable. The magnitude of continued investment and time required to overcome the systemic manufacturing challenges is not viable.
The closure will lead to all Ben Venue employees entering a phased reduction starting this month and continuing into 2014 as Ben Venue executes wind-down activities.
Ben Venue has notified the FDA of its decision.